$TPST
Tempest Therapeutics, Inc. Stock $tpst

$tpst Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000154422722000006 Filed on November 08, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.140M	$2.798M	$3.106M
YoY Change	19.71%	-9.92%	-8.11%
% of Gross Profit
Research & Development	$5.794M	$5.973M	$4.630M
YoY Change	22.88%	29.01%	8.41%
% of Gross Profit
Depreciation & Amortization	$217.0K	$201.0K	$107.0K
YoY Change	112.75%	87.85%	32.1%
% of Gross Profit
Operating Expenses	$8.934M	$5.973M	$4.630M
YoY Change	21.75%	29.01%	8.41%
Operating Profit		-$8.771M	$7.736M
YoY Change		-213.38%	42.36%
Interest Expense	-$432.0K	$389.0K	$437.0K
YoY Change	27.81%	-10.98%
% of Operating Profit			5.65%
Other Income/Expense, Net	$263.0K	-$176.0K	-$374.0K
YoY Change	-355.34%	-52.94%	20.65%
Pretax Income	-$9.103M	-$8.947M	-$8.110M
YoY Change	17.02%	10.32%	27.24%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$9.103M	-$8.947M	-$8.110M
YoY Change	-67.84%	10.32%	49.33%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.66	-$1.21
Diluted Earnings Per Share	-$0.66	-$0.66	-$1.207M
COMMON SHARES
Basic Shares Outstanding	10.52M shares	10.42M shares	6.721M shares
Diluted Shares Outstanding		13.64M shares	6.718M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$31.23M	$42.79M	$59.72M
YoY Change	-39.74%	-28.34%	38.19%
Cash & Equivalents	$31.23M	$42.79M	$59.72M
Short-Term Investments
Other Short-Term Assets	$263.0K	$935.0K	$701.0K
YoY Change	-52.44%	33.38%	-73.38%
Inventory
Prepaid Expenses	$703.0K	$998.0K	$1.300M
Receivables
Other Receivables
Total Short-Term Assets	$32.95M	$60.26M	$62.56M
YoY Change	-52.22%	-3.68%	215.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.060M	$919.0K	$1.116M
YoY Change	-4.76%	-17.65%	0.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$429.0K	$683.0K	$112.0K
YoY Change	286.49%	509.82%	119.61%
Total Long-Term Assets	$13.14M	$2.914M	$4.585M
YoY Change	207.35%	-36.44%	50.92%
TOTAL ASSETS
Total Short-Term Assets	$32.95M	$60.26M	$62.56M
Total Long-Term Assets	$13.14M	$2.914M	$4.585M
Total Assets	$46.09M	$63.17M	$67.14M
YoY Change	-37.07%	-5.91%	193.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.108M	$925.0K	$2.380M
YoY Change	11.81%	-61.13%	122.22%
Accrued Expenses	$2.961M	$2.585M	$1.658M
YoY Change	86.34%	55.91%	149.32%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$3.500M
YoY Change
Total Short-Term Liabilities	$7.277M	$24.06M	$6.203M
YoY Change	-63.66%	287.86%	92.52%
LONG-TERM LIABILITIES
Long-Term Debt	$10.37M	$11.84M	$15.01M
YoY Change	-31.18%	-21.12%
Other Long-Term Liabilities	$10.33M	$503.0K	$2.398M
YoY Change	409.87%	-79.02%
Total Long-Term Liabilities	$10.37M	$11.84M	$15.01M
YoY Change	-31.18%	-21.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.277M	$24.06M	$6.203M
Total Long-Term Liabilities	$10.37M	$11.84M	$15.01M
Total Liabilities	$27.98M	$36.40M	$23.61M
YoY Change	-24.63%	54.19%	376.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$135.8M	-$126.7M	-$92.28M
YoY Change	35.69%	37.26%	28.6%
Common Stock	$11.00K	$10.00K	$7.000K
YoY Change	57.14%	42.86%	-53.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$18.11M	$26.77M	$43.54M
YoY Change
Total Liabilities & Shareholders Equity	$46.09M	$63.17M	$67.14M
YoY Change	-37.07%	-5.91%	193.67%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$9.103M	-$8.947M	-$8.110M
YoY Change	-67.84%	10.32%	49.33%
Depreciation, Depletion And Amortization	$217.0K	$201.0K	$107.0K
YoY Change	112.75%	87.85%	32.1%
Cash From Operating Activities	-$6.479M	-$9.072M	-$11.79M
YoY Change	-18.86%	-23.05%	66.0%
INVESTING ACTIVITIES
Capital Expenditures	$356.0K	-$108.0K	-$24.00K
YoY Change	-1418.52%	350.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$38.00K
YoY Change		-100.0%
Cash From Investing Activities	-$356.0K	-$108.0K	$14.00K
YoY Change	1218.52%	-871.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-4.726M	350.0K	3.167M
YoY Change	52411.11%	-88.95%	-5126.98%
NET CHANGE
Cash From Operating Activities	-6.479M	-9.072M	-11.79M
Cash From Investing Activities	-356.0K	-108.0K	14.00K
Cash From Financing Activities	-4.726M	350.0K	3.167M
Net Change In Cash	-11.56M	-8.830M	-8.608M
YoY Change	44.13%	2.58%	20.14%
FREE CASH FLOW
Cash From Operating Activities	-$6.479M	-$9.072M	-$11.79M
Capital Expenditures	$356.0K	-$108.0K	-$24.00K
Free Cash Flow	-$6.835M	-$8.964M	-$11.77M
YoY Change	-14.11%	-23.81%	65.66%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001544227
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35890
	dei	Entity Registrant Name EntityRegistrantName	Tempest Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-1472564
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7000 Shoreline Court, Suite 275
	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco,
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
	dei	City Area Code CityAreaCode	(415)
	dei	Local Phone Number LocalPhoneNumber	798-8589
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	TPST
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10517099	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42791000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51829000	usd
CY2022Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	15200000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	15000000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2266000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2134000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	60257000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	68963000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	919000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1113000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1312000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3051000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	683000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	111000	usd
CY2022Q3	us-gaap	Assets Assets	63171000	usd
CY2021Q4	us-gaap	Assets Assets	73238000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	925000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	991000	usd
CY2022Q3	us-gaap	Litigation Reserve Current LitigationReserveCurrent	15200000	usd
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	15000000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2585000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1589000	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	3500000	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	871000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1442000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	859000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	912000	usd
CY2022Q3	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	119000	usd
CY2021Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	92000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	24059000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20026000	usd
CY2022Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	489000	usd
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	756000	usd
CY2022Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11836000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	15069000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	503000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2026000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	36398000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	37121000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10517099	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10517099	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6910324	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6910324	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	10000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	153432000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	136173000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-126669000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-100063000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	26773000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36117000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	63171000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	73238000	usd
CY2022Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	5973000	usd
CY2021Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4630000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	16733000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	12451000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2798000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3106000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8973000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7197000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8771000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7736000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-25706000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19648000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	389000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	437000	usd
	us-gaap	Interest Expense InterestExpense	1186000	usd
	us-gaap	Interest Expense InterestExpense	944000	usd
CY2022Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	213000	usd
CY2021Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	63000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	286000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	69000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-176000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-374000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-900000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-875000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-8947000	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-8110000	usd
	us-gaap	Profit Loss ProfitLoss	-26606000	usd
	us-gaap	Profit Loss ProfitLoss	-20523000	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.46
CY2022Q3	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	39000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.49
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.49
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13635927	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13635927	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6717655	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6717655	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10815900	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10815900	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2739602	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2739602	shares
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-89000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-89000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8947000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8199000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26606000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20612000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	36117000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	26773000	usd
CY2022Q1	tpst	Stock Issuance Costs StockIssuanceCosts	44000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1403000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	328000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-8491000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	29357000	usd
CY2022Q2	tpst	Stock Issuance Costs StockIssuanceCosts	343000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7095000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	367000	usd
CY2022Q2	tpst	Warrant Issuance Costs WarrantIssuanceCosts	283000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	7281000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-9168000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	34932000	usd
CY2022Q3	tpst	Stock Issuance Costs StockIssuanceCosts	111000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	350000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	438000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-8947000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-68793000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	20000	usd
CY2021Q1	tpst	Vesting Of Early Exercised Stock Options And Restricted Stock VestingOfEarlyExercisedStockOptionsAndRestrictedStock	57000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	120000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-5355000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-73951000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	29000	usd
CY2021Q2	tpst	Vesting Of Early Exercised Stock Options And Restricted Stock VestingOfEarlyExercisedStockOptionsAndRestrictedStock	39000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	86707000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	30010000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	411000	usd
CY2021Q2	tpst	Adjustments To Additional Paid In Capital Reverse Recapitalization Transaction Costs AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts	6074000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	18001000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-7058000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	48114000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-89000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	48000	usd
CY2021Q3	tpst	Vesting Of Early Exercised Stock Options And Restricted Stock VestingOfEarlyExercisedStockOptionsAndRestrictedStock	37000	usd
CY2021Q3	tpst	Stock Issuance Costs StockIssuanceCosts	349000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3513000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	296000	usd
CY2021Q3	tpst	Adjustments To Additional Paid In Capital Reverse Recapitalization Transaction Costs AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts	346000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	73000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-8110000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-43536000	usd
	us-gaap	Profit Loss ProfitLoss	-26606000	usd
	us-gaap	Profit Loss ProfitLoss	-20523000	usd
	us-gaap	Depreciation Depreciation	421000	usd
	us-gaap	Depreciation Depreciation	272000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1133000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	827000	usd
	tpst	Noncash Lease Expense NoncashLeaseExpense	854000	usd
	tpst	Noncash Lease Expense NoncashLeaseExpense	589000	usd
	tpst	Noncash Interest And Other Expense Net NoncashInterestAndOtherExpenseNet	267000	usd
	tpst	Noncash Interest And Other Expense Net NoncashInterestAndOtherExpenseNet	516000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	336000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-190000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-89000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1130000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	946000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-363000	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	27000	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	89000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1210000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-699000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24593000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17972000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	206000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	108000	usd
	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	0	usd
	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	38000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-206000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-70000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8849000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	33474000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	7280000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	15000000	usd
	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	0	usd
	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	93000	usd
	tpst	Proceeds From Merger Related Cost Financing Activities ProceedsFromMergerRelatedCostFinancingActivities	0	usd
	tpst	Proceeds From Merger Related Cost Financing Activities ProceedsFromMergerRelatedCostFinancingActivities	17045000	usd
	tpst	Payment Of Reverse Recapitalization Transaction Costs PaymentOfReverseRecapitalizationTransactionCosts	0	usd
	tpst	Payment Of Reverse Recapitalization Transaction Costs PaymentOfReverseRecapitalizationTransactionCosts	-6420000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	66000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16129000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	59072000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-89000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8670000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	40941000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51829000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18820000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43159000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59761000	usd
	us-gaap	Interest Paid Net InterestPaidNet	893000	usd
	us-gaap	Interest Paid Net InterestPaidNet	682000	usd
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	884000	usd
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	usd
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	4000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	usd
	tpst	Vesting Of Early Exercise Stock Options VestingOfEarlyExerciseStockOptions	0	usd
	tpst	Vesting Of Early Exercise Stock Options VestingOfEarlyExerciseStockOptions	135000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	30000000	usd
CY2021Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-15
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5365899	shares
CY2021Q2	tpst	Business Combination Exchange Ratio BusinessCombinationExchangeRatio	0.0322
	tpst	Stockholders Equity Note Stock Split Exchange Ratio StockholdersEquityNoteStockSplitExchangeRatio	0.0322
	tpst	Stockholders Equity Note Stock Split Exchange Ratio StockholdersEquityNoteStockSplitExchangeRatio	0.0322
	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development accruals, recoverability of long-lived assets, right-of-use assets, lease obligations, stock-based compensation and income taxes uncertainties and valuation allowances. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates.</span>
CY2022Q3	tpst	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	1271000	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	998000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	949000	usd
CY2022Q3	tpst	Prepaid Research And Development Costs Current PrepaidResearchAndDevelopmentCostsCurrent	333000	usd
CY2021Q4	tpst	Prepaid Research And Development Costs Current PrepaidResearchAndDevelopmentCostsCurrent	632000	usd
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	935000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	553000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2266000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2134000	usd
CY2021Q4	tpst	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	841000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2164000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1937000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1245000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	824000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	919000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1113000	usd
CY2022Q3	us-gaap	Depreciation Depreciation	201000	usd
	us-gaap	Depreciation Depreciation	421000	usd
CY2021Q3	us-gaap	Depreciation Depreciation	107000	usd
	us-gaap	Depreciation Depreciation	272000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1314000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	748000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2585000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1589000	usd
	tpst	Share Based Compensation Arrangements By Share Based Payment Award Optionsassumed In Reverse Recapitalization In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsassumedInReverseRecapitalizationInPeriodWeightedAverageExercisePrice	179.79
CY2022Q1	tpst	Litigation Expense Amount Covered By Insurance LitigationExpenseAmountCoveredByInsurance	15000000	usd
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	15000000	usd
CY2021Q4	us-gaap	Insurance Settlements Receivable InsuranceSettlementsReceivable	15000000	usd
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	15336000	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	3500000	usd
CY2022Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11836000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	100000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	232669	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	19.09
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	25871	shares
CY2021Q2	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	135936731	shares
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	135936731	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	114686731	shares
CY2021Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	114686731	shares
CY2021Q2	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	100187000	usd
CY2020Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	100187000	usd
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	99414000	usd
CY2021Q1	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	99414000	usd
CY2020Q4	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Carrying Amount RedeemableNoncontrollingInterestEquityPreferredCarryingAmount	86706000	usd
CY2021Q2	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Carrying Amount RedeemableNoncontrollingInterestEquityPreferredCarryingAmount	86706000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1.10
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	790637	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.82
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	903527	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.35
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	56235	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	266.80
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1637929	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.72
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	452165	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.35
	tpst	Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Reverse Recapitalization In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationInPeriod	177591	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.77
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	100459	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	107.77
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	736095	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	37.47
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1637929	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M10D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.72
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1637929	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P8Y9M10D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	8.72
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	486089	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y8M15D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	15.22
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	903527	shares
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	438000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	296000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1133000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	827000	usd
CY2021Q3	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	usd
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	usd
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	0	shares
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-8947000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-8110000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-26606000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-20523000	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	13635927	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	6721400	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	10815900	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	2751519	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	0	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	3745	shares
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	11917	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13635927	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13635927	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6717655	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6717655	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10815900	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10815900	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2739602	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2739602	shares
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.49
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.49
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1643965	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	742131	shares

Files In Submission

Name	View Source	Status
0001544227-22-000006-index-headers.html	Edgar Link	pending
0001544227-22-000006-index.html	Edgar Link	pending
0001544227-22-000006.txt	Edgar Link	pending
0001544227-22-000006-xbrl.zip	Edgar Link	pending
ex101-writtenagreementcons.htm	Edgar Link	pending
exhibit311211.htm	Edgar Link	pending
exhibit312211.htm	Edgar Link	pending
exhibit321211.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tpst-20220930.htm	Edgar Link	pending
tpst-20220930.xsd	Edgar Link	pending
tpst-20220930_cal.xml	Edgar Link	unprocessable
tpst-20220930_def.xml	Edgar Link	unprocessable
tpst-20220930_lab.xml	Edgar Link	unprocessable
tpst-20220930_htm.xml	Edgar Link	completed
tpst-20220930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPST
Tempest Therapeutics, Inc. Stock $tpst

2022 Q4 Form 10-Q Financial Statement

#000154422722000006 Filed on November 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST Tempest Therapeutics, Inc. Stock $tpst

2022 Q4 Form 10-Q Financial Statement

#000154422722000006 Filed on November 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST
Tempest Therapeutics, Inc. Stock $tpst